July 1, 2010 – Two companies this week announced plans to join forces to bring expanded proton therapy access to cancer patients in the United States and worldwide. Proton Therapy USA and CareCapital plc have plans to form Proton Therapy Global Management (PTGM), which will design, develop and manage a global network of proton therapy centers, providing access to this specialized and highly effective treatment to the world’s growing population of cancer patients. Proton therapy is a precise form of radiation treatment that has been very successful in treating a wide range of localized tumors, while leaving healthy tissue mostly intact.
PTGM will develop and manage proton therapy facilities in partnership with some of the world’s most prominent hospitals. To date, letters of intent have been signed to build five centers in the United States and United Kingdom, including two leading academic cancer research centers and a site in central London. The company is in the process of launching a funding entity, Proton Therapy Global Inc., that aims to raise several hundred million dollars for investment in individual proton centers.
The founding PTGM team possesses more than 100 years of combined healthcare experience, having held senior executive positions in leading healthcare organizations and global corporations. The management possesses extensive capital markets experience and expertise in structuring facilities management and real estate partnerships.
In addition, the PTGM team has provided critical leadership to the first facility in the world specifically designed to treat cancer patients with proton therapy, which so far has treated more than 15,000 patients. The team has also built and managed hospitals and medical facility projects on four continents.